Sarepta Tells Patients To Stand Down, Golodirsen Future 'Our Responsibility'

 
• By Derrick Gingery
  
MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Sarepta's CEO also said he believed no advisory committee was held for golodirsen because the FDA was moving toward approval. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Pink Sheet